

## Sun Pharma posts net profit of Rs 20,470 M in Q2FY22

02 November 2021 | News

**EBITDA has been reported at Rs 25,608 million, up by 21 per cent over Q2 last year**



Sun Pharmaceutical Industries has reported financials for the second quarter ending September 30, 2021. In Q2FY22 consolidated financials, the sales from operations at Rs 95,567 million, a growth of 13 per cent over Q2 last year. India sales was at Rs 31,878 million, up 26 per cent over the same quarter last year. The US finished dosage sales was at \$361 million, showing a growth of 8 per cent over Q2 last year, the emerging markets sales was at \$243 million, up by 16 per cent over Q2 last year, the Rest of World sales at \$188 million, up by 5 per cent over the same quarter last year. R&D investments have been reported at Rs 5,364 million compared to Rs 6,127 million for Q2FY21, EBITDA at Rs 25,608 million, up by 21 per cent over Q2 last year, with a resulting EBITDA margin of 26.8 per cent. The net profit for the quarter was at Rs 20,470 million, up 29 per cent compared to an adjusted net profit of Q2 last year and up 13 per cent versus reported net profit YoY.

In H1FY22, the consolidated sales from operations was at Rs 192,262 million, a growth of 20 per cent over the same period last year, India sales was at Rs 64,961 million, up by 32 per cent over H1 last year, US finished dosage sales at \$741 million up by 20 per cent over H1 last year. Emerging markets sales has been reported at \$461 million up by 20 per cent over H1 last year. The Rest of World sales was at \$373 million, up by 18 per cent over H1 last year. EBITDA at Rs 53,325 million up 38 per cent over H1 last year, with a resulting EBITDA margin of 27.7 per cent. Excluding the exceptional items, the adjusted net profit for H1FY22 was at Rs 40,263 million, up 47 per cent YoY. The company reported net profit for H1FY22 was at Rs 34,912 million compared to Rs 1,572 million for H1 last year.

Dilip Shanghvi, MD, Sun Pharmaceutical Industries said, "Following our good Q1 performance, we have sustained the positive momentum in Q2 with a topline growth of 13 per cent YoY, driven by broad-based growth across multiple geographies. Our global speciality business has grown by 43 per cent over Q2 last year. Ilumya has grown both YoY and sequentially. Our India business continues to do well with a growth of 26 per cent YoY. We remain steadfast in our focus on growing our overall business and simultaneously strengthening our global speciality portfolio. The recent launch of Winlevi in the US and Ilumya in Canada is a step forward in this direction."